FORM PTO-1	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY DOC TSRI 8			SERIAL NO. 10/527,525	
	UN 2 2 2009		APPLICA Markou,							
INFORMATIO STATEMENT	RADEMARY OF THE		FILING I 10/14/2		GROUP 1617					
		1		PATENT DOCUMENTS			1	T		
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAM	NAME		CLASS	SUB- CLASS	FILING DATE	
						· · · · · · · · · · · · · · · · · · ·				
			FOREIG	N PATENT DOCUMEN	ITS					
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNT			CLASS	SUB- CLASS	TRANSLATION YES NO	
		01	THER DOCUMENTS (I	including Author, Title, D	Date,	Pertinent Pages)			
	1	Waterhouse, et al., Society for	Neuroscience Abstracts	27, No. 2: 2358 (2001)				* ***		
	2	Ahmed, et al., "Neurobiological Evidence for Hedonic Allostasis Associated with Escalating Cocaine Use", Nature Neuroscience 5, No. 7: 625-626 (2002)								
	3	Harrison, et al., "Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats", Neuropsychopharmacology 25, No. 1: 55-71 (2001) Harrison, et al., "Nicotine Potentiation of Brain Stimulation Reward Reversed by DHβE and SCH 23390, but not by Eticlopride, LY 314582 or MPEP in Rats", Psychopharmacology 160: 56-66 (2002)								
	4									
	5	Cryan, et al., "Bupropion Enhances Brain Reward Function and Reverses the Affective and Somatic Aspects of Nicotine Withdrawal in the Rat", <u>Psychopharmacology 168:</u> 347-358 (2003)								
	6	Shigemoto, et al., "Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus", The Journal of Neuroscience 17, No. 19: 7503-7522 (1997)								
1 - 3										
	<u> </u>									
			· · · · · · · · · · · · · · · · · · ·		_					
EXAMINER	· · · · · · · · · · · · · · · · · · ·		<u> </u>	DATE CONS	SIDE	ERED				